Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

EU Commission authorises first DNA vaccine
Clynav will protect Atlantic salmon against Salmon Pancreas Disease.

Clynav will protect salmon against serious infectious disease

The first veterinary DNA vaccine to protect Atlantic salmon against Salmon Pancreas Disease (SPD) had been authorised across the European Union.

SPD is a serious infectious disease which causes damage to the heart, pancreas and skeletal muscle, leading to death in some cases.
The disease has become established in some Member States and outbreaks cause significant loses in salmon farms.

DNA vaccines consist of a genetic sequence that triggers the production of proteins in the cells of the vaccinated animal. These proteins stimulate a protective immune response, thereby preventing or reducing the impact of the disease should the animal be exposed to the virus.

Clynav, marketed by Elanco Europe Ltd, is the first DNA vaccine to be recommended for marketing authorisation in the EU.

Following a series of successful trials, the EMA’s Committee for Veterinary Medical Products (CVMP) considered that the protection provided by the vaccination is clinically relevant and provides direct benefit to the salmon in terms of improved health and welfare.

The CVMP was also satisfied that any potential risk to the environment from use of the product in salmon was negligible. Furthermore, because residues degrade fast in the gastrointestinal tract, the committee concluded that vaccinated salmon are safe to eat.

The Veterinary Medicines Directorate, who steered the authorisation ‘through challenging regulatory hurdles,’ said that the vaccine ‘has the potential to herald a new ear of novel vaccines to protect animals against disease’.

It added that a full summary of Product Characteristics will soon be available through the EMA website and the VMD’s Product Information Database.

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.